From fitness tech and interior design to super thin wearable technology, this week's innovators to know can't be stopped. Courtesy photos

Another week, another set of Houston innovators to keep your eye on. This week's cast of characters are from across industries — from fitness innovation to interior design for tech companies. Scroll through to meet the people behind Houston innovation.

Lizzie DeLacy, founder of DeLacy Wellness

Photo courtesy of DeLacy Wellness

After years of working in fitness, Lizzie DeLacy, founder of DeLacy Wellness, wanted to be able to help more people on their health and wellness journeys. She launched Bodypeace — an app that offers workout sessions, recipes, and tips for a healthier lifestyle — to help people make time for fitness and mindfulness.

"Rather than focusing on really long sessions, though we have a couple in there, we focus on short 5-minute sessions, so anyone can fit movement into their schedule and lifestyle," DeLacy tells InnovationMap. "Additionally, we break it down by body part focus, because oftentimes people don't know necessarily what exact movement or pose or stretch they might need."

Read more about DeLacy and Bodypeace here.

Cunjiang Yu, a Bill D. Cook associate professor of Mechanical Engineering at the University of Houston

Photo courtesy of UH

Cunjiang Yu, a professor and researcher at the University of Houston, is the lead author on a paper that ran as the cover story in Science Advances. In the paper, Yu identifies a wearable technology that can detect health conditions while being so incredibly thin, the wearer might not even notice.

"Everything is very thin, just a few microns thick," says Yu, who also is a principal investigator at the Texas Center for Superconductivity at UH, in a release. "You will not be able to feel it."

Read more about Yu and the technology here.

Amy English, director of interiors for HOK

Photo courtesy of HOK

For most people, the design of an office might be non-consequential. But, for Amy English, director if interiors for HOK, designing the right space can do wonders for your company. English wrote a guest article for InnovationMap that outlines different trends in interior design for tech companies.

"While the next big technological advancement isn't set in stone, one thing is certain: Companies that wish to remain competitive and responsive in the future will need workplaces with the flexibility and personalization that allow their people to gather, connect, innovate, and simply be their best," she writes.

Read English's guest article here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”